John Allan, MD, presents the case of a 72-year-old woman with newly diagnosed chronic lymphocytic leukemia and shares his initial impressions.
A 72-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL)
An expert hematologist-oncologist discusses the patient case and risk stratification for patients with newly diagnosed CLL.
An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.
An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.
John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.
An expert on CLL reviews recent data updates from studies of BTK inhibitors in the frontline setting.
An overview of assessing risk of disease recurrence, steps taken to minimize recurrence, and when to consider second-line treatment for patients with CLL.
An expert hematologist-oncologist offers advice for community oncologists who are treating patients with newly diagnosed chronic lymphocytic leukemia.
John Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
